(CIDRAP News) In the first clinical trial of a norovirus vaccinein which volunteers were deliberately exposed to the common gastrointestinal virusthe inoculation reduced participants' risk of illness by 47%, according to results released recently by LigoCyte Pharmaceuticals, Inc.